Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.

被引：0
|
作者：
Yang, Hongbo
Wong, Michael K. K.
Signorovitch, James E.
Wang, Xufang
Liu, Zhimei
Liu, Nathan S.
Qi, Zhengyun
George, Daniel J.
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] Novartis Pharmaceut, Florham Pk, NJ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4612
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
    Elena, V.
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Ortega, C.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    De Vincenzo, F.
    Procopio, G.
    [J]. BJU INTERNATIONAL, 2012, 110 : 5 - 5
  • [22] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    [J]. ONCOLOGIST, 2023, 28 : S5 - +
  • [23] Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.
    Vogelzang, Nicholas J.
    Pal, Surnanta Kumar
    Signorovitch, James E.
    Reichmann, VVilliam M.
    Chopra, Pooja
    Liu, Zhimei
    Perez, Jose Ricardo
    Jonasch, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [24] Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.
    Heng, Daniel Yick Chin
    Park, Jinhee
    Signorovitch, James E.
    Yang, Hongbo
    Song, Jinlin
    Patel, Dony
    Lin, Chinjune
    Powles, Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [25] HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).
    Tamukong, Patrick
    Kuhlmann, Paige
    You, Sungyong
    Su, Shengchen
    Wang, Yanping
    Small, Eric Jay
    Rini, Brian I.
    Halabi, Susan
    Janes, Jessica
    Freedland, Stephen J.
    Kim, Hyung Lae
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
    Peters, Inga
    Dubrowinskaja, Natalia
    Abbas, Mahmoud
    Seidel, Christoph
    Kogosov, Michael
    Scherer, Ralph
    Gebauer, Kai
    Merseburger, Axel S.
    Kuczyk, Markus A.
    Gruenwald, Viktor
    Serth, Juergen
    [J]. PLOS ONE, 2014, 9 (03):
  • [27] Effect of thoracic radiotherapy in extensive-disease small cell lung cancer on progression-free and overall survival: A retrospective review.
    Wilson, James Matthew
    Grundy, Anna
    Best, Kate
    Mulvenna, Paula M.
    McMenemin, Rhona
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [29] Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience
    Barua, Sasanka Kumar
    Singh, Yashasvi
    Baruah, Saumar Jyoti
    Rajeev, T. P.
    Bagchi, Puskal K.
    Sarma, Debanga
    Phukan, Mandeep
    [J]. WORLD JOURNAL OF ONCOLOGY, 2019, 10 (02) : 101 - 111
  • [30] Atezolizumab Plus Bevacizumab Improves Progression-Free Survival in Metastatic Renal Cell Carcinoma
    Figlin, Robert A.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 423 - 423
12345